105 related articles for article (PubMed ID: 27498732)
1. [Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey].
Katagiri S; Tauchi T; Saito Y; Suguro T; Asano M; Yoshizawa S; Sakuta J; Akahane D; Tanaka Y; Furuya N; Ando K; Fujimoto H; Okabe S; Gotoh M; Ito Y; Ohyashiki K
Rinsho Ketsueki; 2016 Jul; 57(7):873-6. PubMed ID: 27498732
[TBL] [Abstract][Full Text] [Related]
2. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
3. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
[TBL] [Abstract][Full Text] [Related]
4. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
5. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Fava C; Rege-Cambrin G; Dogliotti I; Cerrano M; Berchialla P; Dragani M; Rosti G; Castagnetti F; Gugliotta G; Martino B; Gambacorti-Passerini C; Abruzzese E; Elena C; Pregno P; Gozzini A; Capodanno I; Bergamaschi M; Crugnola M; Bocchia M; Galimberti S; Rapezzi D; Iurlo A; Cattaneo D; Latagliata R; Breccia M; Cedrone M; Santoro M; Annunziata M; Levato L; Stagno F; Cavazzini F; Sgherza N; Giai V; Luciano L; Russo S; Musto P; Caocci G; Sorà F; Iuliano F; Lunghi F; Specchia G; Pane F; Ferrero D; Baccarani M; Saglio G
Haematologica; 2019 Aug; 104(8):1589-1596. PubMed ID: 30819917
[TBL] [Abstract][Full Text] [Related]
6. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
Jiang Q; Liu ZC; Zhang SX; Gale RP
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
[TBL] [Abstract][Full Text] [Related]
7. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
10. Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China.
Jiang Q; Gale RP
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1549-55. PubMed ID: 27085530
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
13. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
14. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
Jiang Q; Yu L; Gale RP
J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
[TBL] [Abstract][Full Text] [Related]
15. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China].
Zhu XJ; You Y; Duan MH; Zhu Y; Liu BC; Chen SN; Du X
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):994-997. PubMed ID: 30612400
[No Abstract] [Full Text] [Related]
17. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
18. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
Legros L; Nicolini FE; Etienne G; Rousselot P; Rea D; Giraudier S; Guerci-Bresler A; Huguet F; Gardembas M; Escoffre M; Ianotto JC; Noël MP; Varet BR; Pagliardini T; Touitou I; Morisset S; Mahon FX;
Cancer; 2017 Nov; 123(22):4403-4410. PubMed ID: 28743166
[TBL] [Abstract][Full Text] [Related]
19. Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Berger MG; Pereira B; Rousselot P; Cony-Makhoul P; Gardembas M; Legros L; Escoffre-Barbe M; Nicolini FE; Saugues S; Lambert C; Réa D; Guerci-Bresler A; Giraudier S; Guilhot J; Saussele S; Mahon FX;
Br J Haematol; 2019 Nov; 187(3):337-346. PubMed ID: 31271217
[TBL] [Abstract][Full Text] [Related]
20. Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A; Ram R; Gafter U; Shpilberg O; Raanani P
Leuk Res; 2010 Jan; 34(1):123-7. PubMed ID: 19640584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]